Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;44(1):73-82.
doi: 10.1007/s40264-020-00995-4.

Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors

Christina E Hoeve  1   2 , Esther de Vries  3   4 , Peter G M Mol  3   4 , Miriam C J M Sturkenboom  5 , Sabine M J M Straus  6   3
Affiliations

Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors

Christina E Hoeve et al. Drug Saf. 2021 Jan.

Abstract

Introduction: When serious medication errors (ME) are identified, communication to the field may be necessary. In the EU, communication of serious safety issues, such as medication errors associated with adverse drug reactions, is done through direct healthcare professional communications (DHPCs). We aimed to identify how often DHPCs about medication errors are distributed, and we explored factors associated with these ME DHPCs.

Methods: We performed a descriptive study of all centrally authorised products (CAPs) approved before 1 May 2019 in the EU. All DHPCs issued between 1 January 2001 and 1 May 2019 were reviewed for ME content. Characteristics of CAPs were collected from the website of the European Medicines Agency. A Kaplan-Meier survival analysis was performed to estimate the 5- and 10-year probability of the occurrence of a first ME DHPC. A logistic regression was performed to explore risk factors for ME DHPCs.

Results: A total of 678 CAPs were included, of which 35 required an ME DHPC during the study period. The 5-year probability for a CAP to have a first ME DHPC was 2.5% (95% CI 1.1-3.9) and the 10-year probability was 4.4% (95% CI 2.2-6.5). Among products with an ME DHPC, the 5-year probability of a second ME DHPC was 21.3% (95% CI 0.2-38.0). The risk of ME DHPCs was increased for products with multiple pharmaceutical formulations, enteral liquid or parenteral injection preparations, and products classified as nervous system agents or antineoplastic and immunomodulating agents.

Conclusions: The absolute number of ME DHPCs for CAPs is low and does not give rise to immediate concern. We identified potential risk factors for ME DHPCs that should be taken into account during approval procedures or line extensions.

PubMed Disclaimer

Conflict of interest statement

CH, EdV, PM, SS have no conflicts of interest directly relevant to this study. Miriam Sturkenboom receives salary for the conduct of a post-authorisation safety study from Novartis through the PHARMO Institute.

Figures

Fig. 1
Fig. 1
Exclusion of non-originator products authorised in the EU during the study period
Fig. 2
Fig. 2
Yearly number of Direct Healthcare Professional Communications for Centrally Authorised Products communicating on medication errors
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organisation . Medication without harm: global patient safety challenge. Geneva: World Health Organisation; 2017.
    1. Ostini R, Roughead EE, Kirkpatrick CM, Monteith GR, Tett SE. Quality use of medicines–medication safety issues in naming; look-alike, sound-alike medicine names. Int J Pharm Pract. 2012;20(6):349–357. doi: 10.1111/j.2042-7174.2012.00210.x. - DOI - PubMed
    1. Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication errors: new EU good practice guide on risk minimisation and error prevention. Drug Saf. 2016;39(6):491–500. doi: 10.1007/s40264-016-0410-4. - DOI - PubMed
    1. Union European. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union. 2010;L348(53):74–99.
    1. European Union. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation. Off J Eur Union. 2010;348(726). Found on: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:000....